| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Section of Nuclear Medicine, Department of Clinical Chemistry, Department of Medical Endocrinology, Surgical Department B and Department of Pathology, Rikshospitalet, Oslo, Norway
Correspondence: For correspondence or reprints contact: Jan G. Fjeld, MD, PhD, Section of Nuclear Medicine, Department of Clinical Chemistry, Rikshospitalet, The National Hospital, N-0027 Oslo, Norway.
ABSTRACT
Parathyroid scintigraphy with the new myocardial perfusion radiopharmaceutical 99mTc-tetrofosmin was compared with 99mTc-sestamibi scintigraphy using early and delayed imaging. Methods: The two preparations were administered on different days to the same 16 patients suffering from primary hyperparathyroidism. Anterior view gamma camera planar imaging (10-min acquisition) was performed in the period between 5 min and 3 hr after administration of the radiopharmaceutical. For most of the patients, a pertechnetate image of the thyroid was available for eyeball comparison when reading the tetrofosmin and sestamibi images. Imaging results were compared with those from histopathological examination after surgery. Results: On early images, all the adenomas visualized with sestamibi were equally well seen with tetrofosmin and vice versa. In 6 of 11 scintigraphically detected neck adenomas, delayed imaging improved the adenoma visualization with sestamibi. In contrast, this differential washout was never seen with tetrofosmin. Histopathological examination of excised tissue specimens after neck exploration (15 patients) or thoracotomy (one patient) revealed a parathyroid adenoma in all 16 patients. Our 12 scintigraphic findings were true-positives, while the remaining four scintigraphies were false-negatives, giving a diagnostic sensitivity of 75% with both preparations. The mediastinal adenoma was detected in a patient with a history of two unsuccessful neck explorations and one unsuccessful thoracotomy. Conclusion: Tetrofosmin has the same success rate as sestamibi for detection of parathyroid adenomas on scintigrams acquired immediately after injection. In contrast to sestamibi, delayed imaging has no diagnostic impact. Moreover, the thyroid/parathyroid differential washout of sestamibi failed in 5 of 11 neck adenomas here detected, indicating that delayed sestamibi washout is an unreliable diagnostic criterion. Therefore, whether sestamibi or tetrofosmin is preferred for parathyroid scintigraphy, thyroid scintigraphy seems mandatory.
Key Words: parathyroid scintigraphy • technetium-99m-tetrofosmin • technetium-99m-sestamibi
This article has been cited by other articles:
|
|
 |
|
  J. R. Smith and M. E. Oates Radionuclide Imaging of the Parathyroid Glands: Patterns, Pearls, and Pitfalls RadioGraphics, July 1, 2004; 24(4): 1101 - 1115. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Spanu, A. Falchi, A. Manca, P. Marongiu, A. Cossu, N. Pisu, F. Chessa, S. Nuvoli, and G. Madeddu The Usefulness of Neck Pinhole SPECT as a Complementary Tool to Planar Scintigraphy in Primary and Secondary Hyperparathyroidism J. Nucl. Med., January 1, 2004; 45(1): 40 - 48. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Mariani, S. A. Gulec, D. Rubello, G. Boni, M. Puccini, M. R. Pelizzo, G. Manca, D. Casara, G. Sotti, P. Erba, et al. Preoperative Localization and Radioguided Parathyroid Surgery J. Nucl. Med., September 1, 2003; 44(9): 1443 - 1458. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Rink, H.-J. Schroth, L.-H. Holle, and H. Garth Limited Sensitivity of Parathyroid Imaging with 99mTc-Sestamibi/123I Subtraction in an Endemic Goiter Area J. Nucl. Med., September 1, 2002; 43(9): 1175 - 1180. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
